N/A N=30 Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.
Injections, Intradermal
Primary: Proportion of Injections Delivered to the Intradermal Layer of the Skin — 28; 30; 30; 30 Injections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Performance and Safety Evaluation of an Intradermal Delivery Device
Injections, Intradermal
Primary: Proportion of Injections Delivered to the Intradermal Layer of the Skin — 1 percentage of injections
Phase 1 N=18 A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs
Healthy
Primary: The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema). — 0; 51; 0; 0 injections
Phase 2 N=227 Higher Dose Intradermal H5 Vaccine
Influenza
Primary: Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 2 — 47; 40 Participants
Phase 2 N=258 Intradermal Influenza Vaccine Study in Elders
Influenza
Primary: Seroprotection Pre- and Post- Vaccination — 18.5; 12.5; 19.1; 15.4 % of Participants
Phase 2 N=22 Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
Dermatitis, Allergic Contact
Primary: Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1 — 5; 9 Participants
Phase 2 N=231 Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Polio Immunity
Primary: Post Booster Polio Neutralizing Antibody Titers — 1715; 976; 1249; 1328 antibody titers
Phase 1 N=223 A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
Herpes Zoster
Primary: Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies — 1.74; 1.64; 3.24; 2.45 Geometric mean fold change
Phase 4 N=31 Pain Outcomes Following Intralesional Corticosteroid Injections
Keloid · Alopecia Areata · Acne
Primary: Pain Outcome: Visual Analog Scale — 5.4; 2.7 Score on a scale
Phase 4 N=170 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
Meningococcal Infections · Meningitis
Primary: Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers — 85; 61; 61; 76 Percentage of participants
Phase 2 N=110 Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults
Influenza
Primary: Categorical Summary of Pain or Other Discomfort Immediately After Vaccination and on Days 3 and 7 Post-vaccination — 85; 75; 4; 2 Participants
Phase 1 N=67 Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
Healthy Volunteers
Primary: Percentage of Participants With Local (Injection Site) Adverse Events (AEs) After Either Vaccine Dose by Maximum Severity as Assessed by the Clinical Staff — 16.7; 11.8…
Phase 4 N=4 Subcutaneous vs. Intramuscular Testosterone
Testosterone Deficiency · Hypogonadism, Male
Primary: Change in Levels of Serum Total Testosterone Concentration — NA; 1043.6; NA; 785.7 ng/dl
Phase 3 N=773 A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
Poliomyelitis
Primary: Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM — 98.1; 95.9; 98.7; 97.9 percentage of seroconversion — p=0.05
Phase 4 N=40 Bacteriostatic Normal Saline Versus Lidocaine for Intradermal Anesthesia
Chronic Pain
Primary: Needle Placement Pain Score — 0; 0 units on a scale
Phase 3 N=4,292 Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines — 23.50; 25.27; 25.29; 24.84 Titer
Phase 4 N=1,250 Jet Injection for Influenza
Influenza, Human
Primary: Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) — 4.43; 4.38; 5.64; 5.64 Titers
Phase 4 N=984 Inactivated Influenza Via Jet Injection
Influenza, Human
Primary: Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) — 3.80; 3.77; 5.72; 5.70 Titers
Early Phase 1 N=7 pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Cutaneous Melanoma, Stage III · Cutaneous Melanoma, Stage IV
Primary: Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs) — 6; 1; 0 Participants
Phase 4 N=871 A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine
Influenza · Vaccination Site Reactions (HT)
Primary: Time to Administer Influenza Vaccine (in Seconds) — 90.0; 182.0; 62.6 seconds
Phase 4 N=116 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®
Vaccine Efficacy
Primary: Humoral Immunity to TBE (Tick-borne Encephalitis) Vaccine — 574.8; 612.0 Geometric mean titers
Early Phase 1 N=24 Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers
Dengue
Primary: Dengue IgG Level — 108.9; 104.0; 158.5; 143.2 RU/ml — p=< 0.01
N/A N=57 Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Age-related Macular Degeneration · Central Retinal Vein Occlusion · Diabetic Macular Edema
Primary: Number of Participants Who Preferred Subconjunctival Anesthetic at the Third Follow-up Visit — 50 participants
N/A N=60 Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection
Trigger Finger
Primary: Difference in Visual-analog Score (VAS) for Anticipated Pain Prior to Injection and Actual Pain After Injection — 1.6; 2.8 units on a scale
N/A N=368 Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
Dermatitis, Atopic
Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…
Phase 3 N=405 ProQuad® Intramuscular vs Subcutaneous
Measles · Mumps · Rubella
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment — 100; 100; 99.3; 99.3 Percentage of participants
N/A N=40 Evaluation of Pain Alleviating Strategies During Allergy Shots
Immunotherapy · Allergy
Primary: Change in Patient Pain Perception Utilizing Three Non-pharmacological Pain Control / Distraction Devices and Ethyl Chloride Spray — 1.33; 2.22; 2.25; 1.45 score on a scale
Phase 1 N=66 A Study of Injections of LY3074828 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3074828 — 9.19; 8.19 microgram/milliliter (ug/mL)
Phase 2 N=77 Intralesional Vitamin D Injection for Treatment of Common Warts
Warts
Primary: Complete Regression of Wart — 12; 10 Participants
N/A N=96 Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe
Tuberculosis
Primary: Injection Site Adverse Events (Following Injection) — 138; 141; 126; 146 Adverse events — p=0.475